ArticleFrontiers in oncology2025
Quality of life outcomes in colorectal cancer survivors: insights from an analytical study at a tertiary cancer center-Qatar.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a major public health concern that affects patients' quality of life (QoL) and imposes challenges on families and healthcare systems. Objectives: To assess QoL and its determinants among CRC patients in Qatar and identify sociodemographic and clinical factors influencing QoL in 2023. Methods: An analytical cross-sectional study was conducted between July and December 2023. From the National Center for Cancer Care and Research (NCCCR) registry, 456 CRC patients were screened, and 169 eligible participants were included. QoL was evaluated using the EORTC QLQ-C30 and the CRC-specific QLQ-CR29 tools. Results: Most patients were aged ≥45 years (80.5%), non-Qatari (79.9%), and married (88.8%). Hypertension (39.1%) and diabetes (31.4%) were the most common comorbidities. Adenocarcinoma was predominant (90.5%), with most cases diagnosed at advanced stages (III-IV, 74.8%) and metastasis in 71.6%. The sigmoid colon was the most common site (34.9%), and combined surgery and chemotherapy were the main treatments (69.2%). Global QoL was moderate to high (70.4 ± 18.5), with fatigue (23.9 ± 26.8) and financial difficulties (28.9 ± 40.4) as the most reported concerns. Functional QoL was higher among those with sufficient income (+12.5 points, p < 0.01) and longer time since diagnosis (+0.06 points/month, p < 0.05), but lower among those with higher education (-5.0 points, p = 0.05) or alcohol use (-11.2 points, p = 0.05). Conclusions: Despite advanced disease stages, CRC patients in Qatar reported good QoL. Socioeconomic status significantly influenced outcomes, highlighting the need for integrated psychosocial and financial support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.